

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First-Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231,  
on the date shown below.

Date: April 4, 2003

By: Carol A. See  
Carol A. See

1653  
#11  
PATENT  
Docket No. GC634-2

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of )  
Bron et al. ) Group Art Unit: 1653  
Serial No.: 09/954,737 ) Examiner: Unassigned  
Filed: September 17, 2001 )  
For: Twin-Arginine Translocation in )  
Bacillus )

RECEIVED

APR 10 2003

TECH CENTER 1600/2900

### Information Disclosure Statement

Commissioner for Patents  
Washington, DC 20231

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

- (a)  accompanies the new patent application submitted herewith. 37 CFR §1.97(a).
- (b)  is filed within three months after the filing date of the application or within three months after the date of entry into the national stage of a PCT application as set forth in 37 CFR §1.491.
- (c)  as far as is known to the undersigned, is filed before the mailing date of a first Office Action on the merits.
- (d)  is filed after the first Office Action and more than three months after the application filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and is accompanied by

either the fee (\$180.00) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Authorization to charge Deposit Account No. 07-1048 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement is provided in the Transmittal Letter submitted herewith in duplicate.

(e)  is filed after the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by authorization (in the Transmittal Letter submitted herewith in duplicate) to charge Deposit Account No. 07-1048 the fee (\$180.00) set forth in 37 CFR §1.17(l)(1) and a certification as specified in 37 CFR §1.97(e), as checked below. **This document is to be considered as a petition requesting consideration of the Supplemental Information Disclosure Statement.**

[If either of boxes (d) or (e) is checked above, the following "certification" under 37 CFR §1.97(e) may need to be completed.] The undersigned certifies that:

Each item of information contained in the Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

No item of information contained in this Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Those patent(s) or publication(s) which are marked with an asterisk (\*) on the attached Form PTO-1449 are not supplied because they were previously cited by or submitted to the Office in a prior application, Serial No. \_\_\_\_\_ filed \_\_\_\_\_.

A copy of the items on Form PTO-1449 is supplied: PCT International Search Report for PCT/US 01/29151, filed September 17, 2001 with attached patents and publications.

each  none  only those which were not submitted in the previous Information Disclosure.

A concise explanation of relevance of the items listed on PTO-1449 is:

- not given
- given for each listed item
- given for only non-English language listed item(s)
- in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.


The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Date: *4 April 2003*



Kamrin T. MacKnight  
Registration No. 38,230

Genencor International, Inc.  
925 Page Mill Road  
Palo Alto, CA 94304-1013  
Tel: 650 846-5838  
Fax: 650 845-6504

## INFORMATION DISCLOSURE CITATION

Attorney Docket No.: GC634-2	Serial No.: 09/954,737	RECEIVED
Applicant: Bron et al.	APR 09 2003	APR 10 2003
Filing Date: September 17, 2001	Group: 1653	TECH CENTER 1600/2900
Page <u>1</u> of <u>1</u>	Date of this Submission: April 4, 2003	

## US PATENT DOCUMENTS

Examiner's	Document				Sub-	Filing
Initial	Number	Date	Name	Class	Class	Date

## FOREIGN PATENT DOCUMENTS

Examiner's	Document				Sub-	Translation
Initials	Number	Date	Country	Class	Class	Yes/No
	WO 02/055717 A2	7/18/02	PCT			
	WO 99/51753	10/14/99	PCT			
	0 444 759 A1	09/04/91	EP			

## OTHER DOCUMENTS

Examiner's	
Initials	Author, Title, Date, Pertinent Pages, etc.
	Jongbloed, Jan D. H. et al., « TatC Is a Specificity Determinant for Protein Secretion via the Twin-arginine Translocation Pathway, » <i>Journal of Biological Chemistry</i> , vol. 275, no. 52, pp. 41350-41357, December 29, 2000.
	Tjalsma, Harold et al., « Signal Peptide-Dependent Protein Transport in <i>Bacillus subtilis</i> : a Genome-Based Survey of the Secretome, » <i>Microbiology and Molecular Biology</i> , vol. 64, no. 3, pp. 515-547, September, 2000.
	Van Dijken, Jan Maarten et al., « Functional genomic analysis of the <i>Bacillus subtilis</i> Tat Pathway for protein secretion, » <i>Journal of Biotechnology</i> , pp. 243-254, September 25, 2002.
	Database EMBL, Blattner F.R. et al., « Hypothetical 11.3 KD Protein in UDP-RFAH Intergenic Region (TATA Protein), Database accession no. 065938, XP002133194.
	Database EMBL, Sargent, F. et al., « TATB Protein, » Database accession no. 069415, XP002133195.
	Database EMBL, Sargent, F. et al., « Sec-Independent Protein Translocase Protein TATC, » Database accession no. P27857, XP002133196.
	Database EMBL, Daniels D. L. et al., « Deoxyribonuclease tatD, » Database accession no. P27859, XP002227139.
	Copy of PCT Search Report
Examiner	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. PTO-1449